☆ 4.6 Review

TCR engineered T cells for solid tumor immunotherapy

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, Research & Experimental

Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial

Cunte Chen et al.

Summary: In this study, the TCR repertoire of early-stage NSCLC patients with EGFR mutation was characterized, showing decreased diversity in patients with the mutation. High TCR diversity was associated with better overall survival, with specific TCR V beta-J beta rearrangements linked to longer survival. These findings suggest a potential novel perspective for adjuvant treatment in resectable NSCLC patients with EGFR mutation.

JCI INSIGHT (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

The role of NFAT in the pathogenesis and targeted therapy of hematological malignancies

Rili Gao et al.

Summary: The NFAT family plays a crucial role in immune response and has been found to be altered in hematological malignancies. Therapeutically targeting NFAT in the treatment of these malignancies could be a promising strategy.

EUROPEAN JOURNAL OF PHARMACOLOGY (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

T-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer

Cornelis J. M. Melief

Summary: Pancreatic ductal adenocarcinoma is the deadliest of all common cancers. The study reported remarkable deep and durable tumor shrinkage in a heavily pretreated patient who received an infusion of autologous T cells transduced.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

Rom Leidner et al.

Summary: The patient with progressive metastatic pancreatic cancer showed regression of visceral metastases after receiving infusion of genetically engineered autologous T cells targeting mutant KRAS G12D, with an overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1. The response was ongoing at 6 months, and the engineered T cells accounted for more than 2% of all circulating peripheral-blood T cells.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial

Fanping Meng et al.

Summary: The study demonstrates that the adoptive transfer of HBV-specific TCR redirected T cells into advanced HBV-HCC patients is generally safe and well-tolerated, with some clinical efficacy observed. These findings support the continued development and eventual application of this treatment strategy in patients with advanced HBV-related HCC.

HEPATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Review Oncology

Targeting CD47 for cancer immunotherapy

Zhongxing Jiang et al.

Summary: Significant progress has been made in targeting CD47 for cancer immunotherapy in solid tumors and hematological malignancies, with a total of 46 clinical trials related to CD47 in the USA and 23 in China. Most of the trials are in early phases, and the new generation CD47 antibodies have shown promising results.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity

Jiangzhou Shi et al.

Summary: The study demonstrates that anti-CD99 CAR T cells can specifically recognize and efficiently eliminate CD99+ leukemia cells.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

Nisha B. Nagarsheth et al.

Summary: In a first-in-human phase 1 trial, T cells targeting HPV-16 E7 showed promising results in treating metastatic epithelial cancers, with objective clinical responses observed in 6 out of 12 patients. This suggests that genetically engineered T cell therapy may be effective in treating common carcinomas, but further studies are needed to understand the resistance mechanisms in advanced epithelial cancer.

NATURE MEDICINE (2021)

添加到收藏夹

Review Immunology

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Qijie Zhao et al.

Summary: This review provides insights into the role of engineered T-cell receptors (TCRs) in immunotherapy and discusses novel approaches to enhance anticancer immune system. It also highlights the importance of safety in genetically modified T cells and explores different strategies such as ImmTAC, HSV-TK, and inducible caspase-9 in cancer immunotherapy. Clinical trials related to TCR-T cell therapy and monoclonal antibodies designed to overcome immunosuppression are also discussed, along with recent advances in understanding TCRs and new approaches to detect antigens and drive effective T cell response.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Hematology

TCR gene-engineered cell therapy for solid tumors

Elaine Tan et al.

Summary: TCR-based cellular therapy has shown promise in targeting solid tumors by recognizing intracellular tumor antigens and inducing cytotoxic responses. Despite various challenges, multiple clinical trials are currently underway to address these limitations.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)

添加到收藏夹

Review Oncology

T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors

Apostolia-Maria Tsimberidou et al.

Summary: TCR-based adoptive therapy uses genetically modified lymphocytes to target specific tumor markers, but faces challenges with TCR product manufacturing, patient selection, and preparation for lymphodepletion. Overcoming these challenges and developing next-generation strategies are crucial for improving the efficacy and safety of TCR-based therapies. Optimization of technology for TCR product generation and patient monitoring for adverse events is necessary.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Christopher T. Su et al.

Summary: The field of multiple myeloma therapy has seen remarkable innovation in recent years, with new therapies on the horizon that have the potential to extend patient survival and move closer to a cure. These emerging therapies include immunotherapy approaches such as chimeric antigen receptor T cells and bispecific T cell engager antibodies, as well as newer generations of monoclonal antibodies and small molecule inhibitors.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Single-Cell RNA-Seq of T Cells in B-ALL Patients Reveals an Exhausted Subset with Remarkable Heterogeneity

Xiaofang Wang et al.

Summary: This study identified two exhausted T cell populations characterized by up-regulation of TIGIT, PDCD1, HLADRA, LAG3, and CTLA4 in B-ALL patients. These exhausted T cells were found to exhibit remarkable heterogeneity, with ten sub-clusters identified based on different cell cycle phases, naive states, and GNLY expression. Coupled with single-cell T cell receptor repertoire profiling, the study suggests diverse origins of the exhausted T cells in B-ALL.

ADVANCED SCIENCE (2021)

添加到收藏夹

Review Oncology

Novel strategies for immuno-oncology breakthroughs with cell therapy

Hongtao Liu et al.

Summary: Cell therapy has advanced rapidly in recent years, with applications expanding beyond hematologic malignancies to solid tumors, targeting personalized tumor-specific neoantigens and enhancing T cell trafficking. Despite challenges, the maturation of technologies in T cell engineering is expected to lead a revolution in cancer immunotherapy in the near future.

BIOMARKER RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

T cell receptor (TCR) signaling in health and disease

Kinjal Shah et al.

Summary: Interaction of T cell receptor with MHC-antigenic peptide complex leads to activation of T cell signaling pathways that mediate gene expression. Adaptor proteins act as scaffolds in integrating these pathways to connect different signaling cascades, facilitating full T cell activation.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Review Hematology

Immune targeted therapy for diffuse large B cell lymphoma

Yaxin Zheng et al.

Summary: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, shows heterogeneous responses to traditional treatment, but immune-targeted therapies have proven effective for refractory and relapsed patients.

BLOOD SCIENCE (2021)

添加到收藏夹

Article Oncology

Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma

Teng Wei et al.

Summary: This study explores the use of TCR-engineered T cells in adoptive cell therapy for treating relapsed and metastatic cancers, by utilizing blood-derived T cells and HLA-matched APCs to overcome challenges in isolating PBMCs from advanced-stage cancer patients. The established protocol provides flexibility in identifying neoantigen-specific TCRs when patient PBMCs and tumor material are not available.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Medical Laboratory Technology

Clinical Value of Serum CEA, CA24-2 and CA19-9 in Patients with Colorectal Cancer

Hui Rao et al.

Summary: The serum levels of CEA, CA24-2, and CA19-9 are valuable indicators for predicting the risk of colorectal cancer, with CEA having the highest sensitivity. The combination of CEA, CA19-9, and CA24-2 can improve the diagnostic sensitivity and specificity of colorectal cancer.

CLINICAL LABORATORY (2021)

添加到收藏夹

Review Oncology

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy

Synat Kang et al.

Summary: NK cells have the ability to lyse tumor targets, but lack specificity. Engineering NK cells with TCR can increase their reactivity and recognition specificity towards tumor cells, which is significant for cancer immunotherapy.

CURRENT ONCOLOGY (2021)

添加到收藏夹

Review Oncology

The Anticancer Potential of T Cell Receptor-Engineered T Cells

Matyas Ecsedi et al.

Summary: Adoptively transferred TCR-transgenic T cells are not restricted by cell surface expression of targets and have the potential to play a key role in cellular cancer immunotherapies. By selecting ideal TCRs, enhancing TCR-T function, expansion, memory formation, and gene-engineering strategies, novel TCR-T therapies can be efficiently deployed.

TRENDS IN CANCER (2021)

添加到收藏夹

Article Oncology

Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy

Joseph P. Sanderson et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Review Oncology

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma

Peter G. Hendrickson et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Article Cell Biology

The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment

Andreas Bikfalvi et al.

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Emerging Landscape of Immune Cell Therapies

Evan W. Weber et al.

CELL (2020)

添加到收藏夹

Article Oncology

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Hanren Dai et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Gene modification strategies for next-generation CAR T cells against solid cancers

Yonggui Tian et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA

Pat Gulhati et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)

添加到收藏夹

Article Oncology

Clinical characteristics and prognostic value of theKRAS G12Cmutation in Chinese non-small cell lung cancer patients

Si-Yang Liu et al.

BIOMARKER RESEARCH (2020)

添加到收藏夹

Review Oncology

Recent advances in CAR-T cell engineering

Ruihao Huang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells

Bruno Sangro et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Oncology

Engineering better chimeric antigen receptor T cells

Hao Zhang et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Immunology

Deciphering CD4+ T cell specificity using novel MHC-TCR chimeric receptors

Jan Kisielow et al.

NATURE IMMUNOLOGY (2019)

添加到收藏夹

Review Oncology

The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review

Jianxiang Zhang et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2019)

添加到收藏夹

Review Oncology

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies

Lorraine Springuel et al.

BIODRUGS (2019)

添加到收藏夹

Review Immunology

T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance

Smita S. Chandran et al.

IMMUNOLOGICAL REVIEWS (2019)

添加到收藏夹

Article Oncology

T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study

Stacey L. Doran et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma

Yuexin Xu et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

添加到收藏夹

Review Immunology

Engineered T Cell Therapy for Cancer in the Clinic

Lijun Zhao et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

Indu Ramachandran et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Oncology

T cell receptor-engineered T cells for leukemia immunotherapy

Yikai Zhang et al.

CANCER CELL INTERNATIONAL (2019)

添加到收藏夹

Review Immunology

Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers

Lei Chen et al.

IMMUNOLOGY LETTERS (2019)

添加到收藏夹

Article Medicine, General & Internal

NK cells specifically TCR-dressed to kill cancer cells

Nadia Mensali et al.

EBIOMEDICINE (2019)

添加到收藏夹

Article Oncology

Identification of TCR V11-2-D1-J1-1 T cell clone specific for WT1 peptides using high-throughput TCR gene sequencing

Yikai Zhang et al.

BIOMARKER RESEARCH (2019)

添加到收藏夹

Review Oncology

T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies

Melinda A. Biernacki et al.

CANCER JOURNAL (2019)

添加到收藏夹

Review Immunology

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

Remy Thomas et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Pathology

PRAME Expression in Melanocytic Tumors

Cecilia Lezcano et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model

Benjamin Y. Jin et al.

JCI INSIGHT (2018)

添加到收藏夹

Article Pathology

Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1

Kunio Iura et al.

HUMAN PATHOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Justin Eyquem et al.

NATURE (2017)

添加到收藏夹

Article Cell Biology

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

Waseem Qasim et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

添加到收藏夹

Review Immunology

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

Nisha Nagarsheth et al.

NATURE REVIEWS IMMUNOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Improving homing in T cell therapy

Debora Vignali et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2017)

添加到收藏夹

Review Critical Care Medicine

New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management

Frank Kroschinsky et al.

CRITICAL CARE (2017)

添加到收藏夹

Article Immunology

The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4(+) T Cells after Intercellular Antigen Transfer

Jean Francois Fonteneau et al.

JOURNAL OF IMMUNOLOGY (2016)

添加到收藏夹

Article Immunology

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice

Marie-Louise Sentman et al.

JOURNAL OF IMMUNOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Ionic immune suppression within the tumour microenvironment limits T cell effector function

Robert Eil et al.

NATURE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes

Alla N. Shatrova et al.

PLOS ONE (2016)

添加到收藏夹

Article Oncology

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

David T. Teachey et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Oncology

Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer

Xianfeng Zha et al.

ONCOTARGET (2016)

添加到收藏夹

Review Oncology

Toxicity and management in CAR T-cell therapy

Challice L. Bonifant et al.

MOLECULAR THERAPY-ONCOLYTICS (2016)

添加到收藏夹

Article Oncology

Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

Shinichi Kageyama et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient

Waseem Qasim et al.

JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

Joost H. van den Berg et al.

MOLECULAR THERAPY (2015)

添加到收藏夹

Article Oncology

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Paul F. Robbins et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Thinle Chodon et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

B. Berdien et al.

GENE THERAPY (2014)

添加到收藏夹

Article Immunology

PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation

Muhammad Zaeem Noman et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2014)

添加到收藏夹

Article Biotechnology & Applied Microbiology

RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer

Mario Bunse et al.

MOLECULAR THERAPY (2014)

添加到收藏夹

Article Hematology

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Gerald P. Linette et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

Daniel Abate-Daga et al.

BLOOD (2013)

添加到收藏夹

Review Oncology

The role of peptide and DNA vaccines in myeloid leukemia immunotherapy

Chen Lin et al.

CANCER CELL INTERNATIONAL (2013)

添加到收藏夹

Article Oncology

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Richard A. Morgan et al.

JOURNAL OF IMMUNOTHERAPY (2013)

添加到收藏夹

Review Biotechnology & Applied Microbiology

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

Thomas Gaj et al.

TRENDS IN BIOTECHNOLOGY (2013)

添加到收藏夹

Review Oncology

New insights into antigen specific immunotherapy for chronic myeloid leukemia

Yangqiu Li et al.

CANCER CELL INTERNATIONAL (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

Elena Provasi et al.

NATURE MEDICINE (2012)

添加到收藏夹

Article Hematology

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety

Toshiki Ochi et al.

BLOOD (2011)

添加到收藏夹

Article Oncology

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies

Sid P. Kerkar et al.

JOURNAL OF IMMUNOTHERAPY (2011)

添加到收藏夹

Article Biotechnology & Applied Microbiology

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Maria R. Parkhurst et al.

MOLECULAR THERAPY (2011)

添加到收藏夹

Article Immunology

Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase

Timothy L. Frankel et al.

JOURNAL OF IMMUNOLOGY (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

Gavin M. Bendle et al.

NATURE MEDICINE (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Mixed T cell receptor dimers harbor potentially harmful neoreactivity

Marleen M. van Loenen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

添加到收藏夹

Article Hematology

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Laura A. Johnson et al.

BLOOD (2009)

添加到收藏夹

Article Immunology

MAGE A3 antigen-specific cancer immunotherapeutic

Nir Peled et al.

IMMUNOTHERAPY (2009)

添加到收藏夹

Article Immunology

alpha beta T Cell Receptor Transfer to gamma delta T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo

Lars T. van der Veken et al.

JOURNAL OF IMMUNOLOGY (2009)

添加到收藏夹

Article Oncology

T-cell receptor gene therapy of established tumors in a murine melanoma model

John D. Abad et al.

JOURNAL OF IMMUNOTHERAPY (2008)

添加到收藏夹

Article Oncology

V gamma 9V delta 2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas

Francoise Bouet-Toussaint et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Cancer regression in patients after transfer of genetically engineered lymphocytes

Richard A. Morgan et al.

SCIENCE (2006)

添加到收藏夹

Article Oncology

αβ T-cell receptor engineered γδ T cells mediate effective antileukemic reactivity

LT van der Veken et al.

CANCER RESEARCH (2006)

添加到收藏夹

Article Oncology

Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE

Y Miyahara et al.

CLINICAL CANCER RESEARCH (2005)

添加到收藏夹

Article Oncology

Ex vivo expansion of CD8+CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin

HJ Wajchman et al.

CANCER RESEARCH (2004)

添加到收藏夹

Article Immunology

Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient

S Mandruzzato et al.

JOURNAL OF IMMUNOLOGY (2002)

添加到收藏夹

Article Immunology

Functional reconstitution of class II MHC-Restricted T cell immunity mediated by retroviral transfer of the αβ TCR complex

K Fujio et al.

JOURNAL OF IMMUNOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.